U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
IPSEN (OTCMKTS:IPSEY) was downgraded by analysts at UBS Group AG to a "neutral" rating.
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue